Gliomas are one of the most malignant cancers. The molecular bases regulating the onset of such tumors are still poorly understood. The translocator protein (TSPO), formerly known as the peripheral-type benzodiazepine receptor, is a mitochondrial permeability transition (MPT)-pore protein robustly expressed in gliomas and involved in the regulation of apoptosis and cell proliferation. TSPO expression levels have been correlated with tumor malignancy. Here we describe the production of C6 rat glioma cells engineered to over-express the TSPO protein with the aim of providing the first direct evidence of a correlation between TSPO expression level and glioma cell aggressiveness. We observed that TSPO potentiates proliferation, motility and transmigration capabilities as well as the ability to overcome contact-induced cell growth inhibition of glioma cells. On the whole, these data demonstrate that TSPO density influences metastatic potential of glioma cells. Since several data suggest that TSPO ligands may act as chemotherapeutic agents, in this paper we also demonstrate that TSPO ligand-induced cell death is dependent on TSPO density. These findings suggest that the use of TSPO ligands as chemotherapeutic agents could be effective on aggressive tumor cells with a high TSPO expression level.
Introduction
The translocator protein (18kDa) (TSPO), formerly known as the peripheral-type benzodiazepine receptor (PBR) [1] , is an abundant mitochondrial protein expressed in peripheral tissues, as well as in astrocytes and microglial cells within the central nervous system (CNS) [2, 3] . Increased TSPO expression has been observed in cancer, including brain tumors [4] [5] [6] [7] [8] . TSPO has been implicated in many physio-pathological conditions including apoptosis, microglial activation related to brain damage, steroidogenesis, and cell proliferation [9] . In mitochondria, TSPO is associated with other proteins, including the voltage-dependent anion channel (VDAC) and the adenine nucleotide carrier (ANT), making up the mitochondrial permeability transition (MPT)-pore [10] whose modulation has been suggested as a critical event in the regulation of processes underlying cellular survival/death [2, [10] [11] [12] . It has been demonstrated that specific TSPO ligands show proapoptotic activity and may act, through the modulation of the MTP-pore opening, as potential drugs useful in cancer therapy [5, [13] [14] [15] [16] [17] . Among tumors, gliomas represent an elective target for TSPO ligand mediated chemotherapy; this protein being virtually absent in the neurons and over-expressed in glioma with respect to normal glial cells [3, [18] [19] [20] [21] [22] .
It is interesting to note that TSPO expression level positively correlates with cell malignancy in several tumors including gliomas [18, [23] [24] [25] [26] [27] [28] . However, the role of TSPO up-regulation in brain tumor cells is still puzzling. For these reasons over the last years we have been focusing our attention on the study of TSPO and TSPO ligand effects in glioma aggressiveness. Up to now no studies have been performed by direct comparison of brain tumor cells engineered to over-express TSPO with wild type cells of the same cell line. Here, we describe the production of glioma cells engineered to over-express the TSPO and examine the relationship between TSPO up-regulation and growth, motility, transmigration and susceptibility to the TSPO ligand PK 11195-induced apoptosis of glioma cells.
Materials and methods

Cell cultures
Rat C6 glioma cells (a kind gift from Professor Damir Janigro, Cleveland Clinic Foundation, Cleveland, OH) were cultured as described in [15] .
RNA isolation, reverse transcription-PCR, and cloning of rat TSPO
Total RNA was extracted from 5 × 10 6 cells using the Nucleospin RNA II kit (Macheray-Nagel) according to the manufacturer's instructions. For RT-PCR, about 1μg DNase-digested total RNA was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen) following the recommendations of the manufacturer. Full-length cDNA of TSPO was amplified using TSPO specific forward primer (5'CCCAAGCTTATGTCTCAATCCTGGG-TACC3') containing a restriction site for the endonuclease Hind III at the 5' end and a TSPO specific reverse primer (5'GCGAGGATCCAAAGCAG-GATGACCTCAACC3') containing a restriction site for the endonuclease BamH I at the 5' end. The conditions for PCR were as follows: 2min at 95°C, 30 cycles of 30s at 95°C, 1min at 55°C, and 30s at 72°C. A final extension was carried on at 72°C for 7min. The amplified fragment was Hind III and BamH I digested and then cloned into the vector pFLAG-cmv-2 (Sigma) in frame with a short flag epitope in the amino terminal position. After transformation in competent Escherichia coli cells, some clones were isolated and plasmid DNAs were sequenced by automated fluorescent cycle sequencing (ABI). One of these clones (TSPO-pFLAG-cmv-2) was used in the following applications.
Transfection
For transfection, 2μg of TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 (control) were mixed with 10μL Lipofectamine 2000 reagent (Invitrogen) in 0.5mL of Optimem (Gibco). 90% confluent C6 glioma cells were transfected with the mixture and incubated for 6h according to the manufacturer's instructions. Then the transfection medium was replaced with complete medium and the cells were used for experiments.
Western blot analysis
Whole cell extracts of TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 transfected C6 cells were used for Western blot analysis. 24, 48, 72 and 96h after transfection C6 cells were detached with 2mM EDTA, collected by centrifugation (1000g for 5min) and lysed by adding 80μL of lysis buffer (1% Triton X100, 10% glycerol, 20mM Tris-HCl pH 7.5, 150mM NaCl, 10mM EDTA, 1mM phenylmethylsulphonyl fluoride (PMSF), 0.5μM aprotinin, 0.5μM leupeptin) for 30min on ice. Then samples were frozen-thawed for three times and centrifuged to collect the supernatants. Protein concentration was measured by using the Micro BCA protein assay kit (Pierce). 25μg of proteins were separated on a SDS-PAGE gel and electrotransferred onto a nitrocellulose membrane. After blocking with 5% non-fat dry milk (Biorad) in TPBS (50nM Tris, 150nM NaCl, 0.05% Tween 20) for 4h at room temperature, the FLAG-TSPO recombinant protein was detected by adding mouse anti-FLAG antibody (Sigma, 1:1000) in 3% non-fat dry milk in TPBS for 1h at room temperature. Filters were then washed in TPBS and incubated for 1h at room temperature with 1:100 000 dilution of POD-conjugated anti-mouse IgG antibody (Biorad). After several washes in TPBS, signal cross-hybridization was revealed by chemoluminescence using the Supersignal West Dura substrate (Pierce). To test that an equal amount of total proteins was loaded in each line, after FLAG-TSPO revelation, filters were stripped and re-probed with mouse anti-ERK antibody (Santa Cruz, 1:1000) and revealed as described above.
Radioligand binding assays
Membranes from transfected C6 glioma cells with TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 (collected 24h after transfection) were prepared as previously described by Gorman et al. and Veenman et al. [28, 29] with minor modifications. Briefly, confluent cells were washed with phosphate-buffered saline, harvested by scraping and collected by centrifugation at 1000×g for 10min at 4°C. Cell pellet was suspended in 5mM Tris-HCl buffer, pH 7.4 containing 160μg/ml benzamidine, 200μg/ml bacitracin and 20μg/ml trypsin inhibitor, homogenized using Ultraturrax homogenizer and centrifuged at 48 000×g for 15min at 4°C. Pellet was suspended in 50mM Tris-HCl buffer, pH 7.4 (assay buffer), homogenized and centrifuged at 48 000×g for 15min at 4°C. Protein content was estimated by the Bradford method [30] using the Bio-Rad Protein Assay reagent, according to the manufacturer's protocol, with bovine serum albumin (BSA) as standard.
[ 3 H]PK 11195 (specific activity 69.9Ci/mmol) binding assays were conducted incubating cell membranes (40μg of protein), with 0.5-26nM [ 3 H] PK 11195 in a final volume of 500μl of 50mM Tris/HCl, pH 7.4 buffer. Nonspecific binding was determined in the presence of 1μM unlabelled PK 11195. Binding equilibrium was reached following a 90min incubation at 0°C. Samples were filtered rapidly under vacuum through GF/C glass fiber filters, and washed four times with 3ml of assay buffer. Finally, filters were placed in vials containing 4ml of scintillation liquid and bound radioactivity was measured by a scintillation counter (Tri-Carb 2800 TR, Perkin-Elmer).
Scatchard analyses of saturation binding data, graphic presentation and statistical analyses were performed using the non-linear multipurpose curvefitting Graph-Pad Prism computer program (Graph Pad Software, version 4.0; San Diego, CA). In detail, for saturation binding experiments one-site binding curve-fitting was used.
Immunofluorescence microscopy
Approximately 2 × 10 4 TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 transfected C6 cells were plated onto poly-D-lysine slides and incubated overnight. Cells were then fixed in paraformaldehyde (4%) for 30min at room temperature, washed in PBS and blocked in blocking solution (0.1% Triton X-100, 0,5% bovine serum albumin in PBS) for 30min. Then, cells were incubated for 1h at room temperature in blocking solution containing rabbit anti-FLAG antibody (Sigma, 1:100) and mouse anti-cytochrome c antibody (Santa Cruz, 1:50). After washing in PBST (0.1% Triton in PBS), cells were incubated for 1h at room temperature in blocking solution containing FITC-conjugate anti-rabbit secondary antibody, (1:200, Invitrogen) and rhodamine-conjugate anti-mouse secondary antibody (1:200, Santa Cruz). Slides were then mounted and analyzed under the Axioplan fluorescent microscope (Zeiss).
Cell proliferation assays
To determine the proliferation rate, the same number (4000 cells per well) of TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 transfected C6 cells, were seeded in 24-well plates, immediately after transfection, and allowed to proliferate for 24, 48, 96h. Both attached and floating cells were taken for counting with a hemocytometer. We designed this experiment in way to maintain cells in the exponential phase of growth (not confluent) up to about 120h. For each cell line the experiment was performed on three independent transfections. The growth curves were confirmed repeating the entire experiment for three times. The number of TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 transfected C6 cells was also evaluated after they had been confluent for 3days. For this last analysis, 90% confluent C6 glioma cells were transfected with TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 vectors as described above. Three days after transfection the medium covering cells was collected, the adherent cells trypsinized, added to the collected medium and counted with a hemocytometer. For each cell line the experiment was performed on ten independent transfections To calculate the mitotic index of C6 cells over-expressing TSPO, 6-well plates containing 90% confluent C6 glioma cells were transfected with TSPOpFLAG-cmv-2, pFLAG-cmv-2, or pEGFP-C1 (a vector that drives the expression of the Green Fluorescent Protein in the cytoplasm). Three independent transfections were performed for each vector. Six hours after transfection, cells of each well were detached and split into three 6-well plates (to reach 30% confluence) and allowed to proliferate for 24 and 72h.
Cells were then detached, collected by centrifugation and resuspended in 40μl of glycerol, acetic acid, PBS (1:1:13) solution containing 1× Hoechst. Two 5μl aliquots of cell suspension for each sample were spotted on a glass slide and allowed to dry. The number of mitotic figures was counted under the fluorescence microscope Axiovert 25 (Zeiss). Two 10μl aliquots for each sample were used to count the number of total cells with a hemocytometer. For each cell line the mitotic index [(mitotic figures/total cells) × 1000] was calculated in 9 replicate wells. Two independent experiments were performed.
Motility assay
Equal amounts of C6 cells were plated in 6-well plates (95% confluent), transfected with TSPO-pFLAG-cmv-2, pFLAG-cmv-2 or pEGFP-C1 and a scratch (to remove cells) was done along the diameter of all 6-well plates 6h after transfection. Photographs were taken immediately after scratching (T0) in three different points along the scratch. 20, 25, 40h after the scratch the same points were photographed at the same magnification to determine the colonization of the scratch. The scratch of each picture was measured by using the Adobe Photoshop ruler. The migration rate (cm/h) was calculated for each treatment considering the mean difference between the scratch width at T0 and at each time of analysis in the three photographed points. For each cell line the experiment was performed on six independent transfections.
Transmigration assay
Cell ability to transmigrate was assayed in modified Boyden chambers (Neuro Probe). 10% FBS in C6 growth medium supplemented with 0.1% BSA was placed in the lower chamber as source of chemoattractant. Polyvinylpyrrolidone-free 8μm-pore polycarbonate filters were coated with 5mg/L porcine skin gelatin (Sigma) and placed between upper and lower chambers. TSPO-pFLAGcmv-2 or pFLAG-cmv-2 transfected C6 cells were trypsinized, resuspended in growth medium supplemented with 0.1% BSA and then placed in the upper chamber at a density of 2 × 10 5 cells for chamber. After 5h of incubation at 37°C in a humidified atmosphere, filters were fixed in absolute ethanol for 30s and stained with 2% toluidine blue (Sigma) for 10min at room temperature. Cells incapable of migrating were gently scraped from the upper side of the filter, while migrated cells were counted. Fifteen microscope fields (10×) for each filter were counted.
Cell viability analysis by MTS conversion assay
TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 transfected C6 cells were seeded in 96-well plates at a density of 1 × 10 4 cells per well. The following day or 96h after transfection, the culture medium was replaced with fresh medium supplemented with different PK 11195 concentrations (1-100μM). Each cell line has also been treated with the vehicle ethanol. Twentyfour hours after the treatment the number of living cells was measured by quantitative colorimetric MTS assay (Promega) using a microplate reader (Wallac Victor 2, 1420 Multilabel counter, Perkin-Elmer) as previously described by [15] .
Each treatment was performed in duplicate and three independent experiments were performed.
Graphic presentation and data analysis were performed using the non-linear multipurpose curve-fitting Graph-Pad Prism computer program (Graph Pad Software, version 4.0; San Diego, CA).
Results
TSPO over-expression in C6 rat glioma cells
TSPO cDNA was isolated by RT-PCR using C6 total RNA as template, and cloned in pFLAG-cmv-2 vector in frame with the nucleotide sequence encoding the eight amino acid FLAG peptide (at the N-terminus of TSPO). The cDNA sequence isolated from C6 cell was identical to that deposited in DDBJ/ EMBL/GenBank under accession number NM_012515. To assess the effectiveness of our expression system, the expression of the FLAG-tagged TSPO was initially monitored by immunoblotting on whole extract of TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 cells obtained 24, 48, 72 and 96h after transfection. Anti-FLAG antibody revealed the presence of a cross-reactive band of the expected molecular weight (20kDa) in TSPO-pFLAG-cmv-2 transfected samples. Interestingly, no SDS and beta-mercaptoethanol resistant polymers were found with anti-FLAG antibodies. The recombinant protein was expressed at high level in samples collected 24h after transfection and its expression was significantly reduced in cell extracts collected 48 and 72h after transfection. Recombinant protein was no longer detectable in the extracts collected 96h after transfection (Fig. 1A) . No cross-reactive bands were visible in whole extract obtained from pFLAG-cmv-2 transfected cells (control cells).
In order to verify if the introduction of the FLAG epitope at the N-terminus of TSPO could modify the binding affinity for the specific and selective TSPO ligand, PK 11195, homogenate membranes of TSPO-pFLAG-cmv-2 transfected cells, collected 24h after transfection, were used for saturation studies of specific [ 3 H]PK 11195 binding. Scatchard analysis of [ 3 H]PK 11195 binding saturation data revealed a single population of binding sites with a dissociation constant (Kd)value of 5.0 +/− 0.52nM.C6 glioma cells transfected with TSPO-pFLAG-cmv-2 showed higher levels (about 2 folds) of [ 3 H]PK specific binding sites than control cells (Fig. 1B) .
We also analyzed the sub-cellular localization of TSPOpFLAG recombinant protein by immunofluorescence microscopy. Anti-FLAG antibody revealed a cytoplasmic localization of TSPO-FLAG protein that appeared accumulated in welldefined sub-cellular structures ( Fig. 2A) . Co-localization experiments performed by using anti-cytochrome c antibody as a mitochondrial marker (Fig. 2B ) revealed an exclusive mitochondrial localization for TSPO-FLAG recombinant protein (Fig. 2) .
TSPO over-expression increases the proliferation capabilities of C6 glioma cells
With the aim of analyzing the relationship between TSPO expression level and cell growth (Fig. 3) , we assessed TSPOpFLAG-cmv-2, pFLAG-cmv-2 or pEGFP-C1 transfected cell mitotic index. As shown in Fig. 3C , TSPO-pFLAG-cmv-2 transfected cells showed a higher mitotic index then control cells 1day after transfection. This difference became less pronounced 3days after transfection when, according to Western blot analysis, the expression of TSPO recombinant protein is strongly reduced (data not shown). Further support for TSPO positive influence on cell proliferation, derived from the analysis of TSPO-pFLAG-cmv-2, pFLAG-cmv-2 or pEGFP-C1 transfected cell proliferation curves. As reported in Fig. 3A , TSPO-pFLAG-cmv-2 transfected C6 cells have a higher proliferation rate than control cells. Significant differences appeared 72h after seeding ( ⁎ p b 0.05). Although this data could appear in disagreement with the early effect of TSPO upregulation on mitosis, it has to be taken in mind that we designed our experiments in way to maintain cells in the exponential phase of growth up to about 120h. Thus, the difference in cell number (also if small) that is produced by TSPO over-expression during the first days is amplified in the following days as long as one of the cell lines reaches the confluence and reduces cell growth rate. We also evaluated the ability of TSPO-pFLAG-cmv-2 or pFLAG-cmv-2 transfected C6 cells to grow after having reached the confluence to test TSPO influence on cell ability to overcome contact-induced cell growth inhibition. As reported in Fig. 3B the number of TSPO-pFLAG-cmv-2 transfected C6 cells was 25% higher (p b 1 × 10 − 5 ) than that of control cells.
TSPO over-expression increases migration rate of C6 glioma cells
With the aim of analyzing the relationship between TSPO expression level and cell migration capabilities, we assessed the rate at which controls (pFLAG-cmv-2 and pEGFP-C1) or TSPOpFLAG-cmv-2 transfected cells recovered a scratch done on a layer of confluent cells. Colonization of the scratch was monitored 20, 25 and 40h after the scratching. As reported in Fig. 4 , TSPOpFLAG-cmv-2 transfected C6 cells reduced the clear area (Fig. 4  A,B) and migrated into the scratch at a significantly higher rate than that of controls cells (p b 0.05) (Fig. 4C) .
TSPO over-expression increases transmigration capabilities of C6 glioma cells
One of the most important characteristics of aggressive tumoral cells is the ability to penetrate anatomic barriers and diffuse in cell matrix. Therefore, we assessed C6 tumor cell transmigration across artificial barrier in vitro to evaluate tumor cell invasion properties of TSPO-pFLAG-cmv-2 transfected cells and control cells. We separated populations of cells able to invade a gelatin layer and counted the number of cells that reached the lower side of a polycarbonate filter. As reported in Fig. 5 , the number of cells that more actively invade the gelatin layer was significantly higher in TSPO-pFLAG-cmv-2 transfected C6 than control cells (p b 0.05).
TSPO over-expression sensitizes C6 glioma cells to TSPO specific ligand treatment
To assess whether the TSPO over-expression affects C6 cell sensitivity to the pro-apoptotic activity of its specific ligand PK 11195, we evaluated cell viability of control and TSPO-pFLAGcmv-2 transfected cells following 24h exposure to micromolar increasing PK 11195 concentrations. The 24h treatment was started 24 or 96hours after transfection. As shown in Fig. 6 , PK 11195 caused a concentration-dependent inhibition of C6 cell viability in both TSPO-pFLAG-cmv-2 transfected and control cells treated starting from the 24th hour after transfection. Interestingly, we observed that TSPO-pFLAG-cmv-2 transfected C6 cells showed a higher sensitivity to the antiproliferative activity of PK 11195 in comparison with control cells. These differences were observed for each PK 11195 concentration. According to the strong reduction in recombinant TSPO expression that occurs 96h after transfection, no more differences in sensitivity to PK 11195 were observable when the treatment was initiated 96h after transfection.
Discussion
In recent years attention has been focused on TSPO role in the regulation of cell proliferation, as several literature data report that TSPO is strongly up-regulated in tumoral tissues or tumor cell lines with respect to untransformed control tissues [4] [5] [6] [7] [8] . Much attention has been turned to TSPO as a promising protein target for chemotherapy, suggesting its ligands as potential therapeutic drugs [13] [14] [15] [16] [31] [32] [33] . However, only indirect data are available to elucidate the meaning of TSPO upregulation on tumor cells. TSPO is highly expressed in glioma cells and to understand the role of its up-regulation in glioma aggressiveness we produced, for the first time, genetically modified glioma cells over-expressing TSPO protein and we evaluated the influence of TSPO density on the typical features that give an invasive/aggressive phenotype (i.e. proliferation, motility and transmigration capabilities) to a tumor cell. Among glioma cell lines we selected C6 cells because we previously characterized in this cell line TSPO expression and sub-cellular localization and established cell response to TSPO ligand treatment [15, 16] .
By Western blot analysis, TSPO recombinant protein expression was detectable 24h after transfection and some of it remained up to 72h, a sufficiently long period to carry out functional studies. Radioligand binding assays demonstrated that the FLAG epitope addition to the amino terminus of TSPO does not change the binding affinity for this ligand. Indeed, the [ 3 H]PK 11195 binding affinity for FLAG-tagged TSPO resulted comparable to that previously reported for native rat C6 glioma cells [29] [16] .
These results demonstrate the success in producing C6 cells over-expressing a recombinant TSPO protein with peculiarities similar to those of the endogenous TSPO protein and pushed us to undertake functional experiments to test the proliferation, motility and transmigration properties of C6 cells overexpressing the TSPO protein. We found that TSPO overexpression increased C6 cell proliferation rate and the mitotic index as well as the cell ability to overcome the contactdependent inhibition of cell growth, a feature that is linked to tumor invasion capabilities. Moreover we found that TSPO over-expression improved the motility rate and transmigration capability of C6 cells, demonstrating that the increase of TSPO expression level may contribute to the acquisition of an invasive/aggressive phenotype in gliomas. This is the first direct evidence that TSPO density influences glioma cell aggressiveness and is consistent with previous reports that correlate TSPO expression level and tumor malignancy grade [18, 23, 24, 28] .
Our data agree with recent findings, obtained in breast cancer cells, demonstrating that a siRNA mediated reduction of TSPO endogenous level and TSPO over-expression induces a decrease and an increase in cell proliferation, respectively [34] . However, all these data are in contrast with a previous report describing that TSPO knockdown by stable antisense transfection induces an increase of in vitro tumorigenicity and a reduction of apoptosis in C6 cells [35] . These authors have suggested that increased cell proliferation in TSPO knockdown cells was due to a loss of TSPO-related apoptosis. According to these interpretations, we should have found an increase in apoptotic cell death and a reduced proliferation rate in TSPO overexpressing cells. Contrarily, in our experimental condition, we did not find an increase in the number of dead cells and, in addition, TSPO transfected cells proliferated at higher a rate than controls. Although apparently contrasting, these findings could be explained by the idea that TSPO could be found, inside the outer mitochondrial membrane, as a monomer, heteropolymer or SDS and beta-mercaptoethanol resistant homopolymer. In the heteropolymers, TSPO is bound to the mitochondrial permeability transition pore proteins [9, 36] and the heteropolymerization of TSPO in the pore complex is limited by the density of VDAC [37] . The silencing of TSPO expression affects the monomeric, the homopolymeric as well as the heteropolymeric forms. On the contrary, the overexpression of the FLAG-TSPO in the C6 cell mitochondrial membranes preferentially acts by increasing the monomeric TSPO. Indeed, the amount of the heteromeric TSPO is limited by VDAC density and unlikely the number of heteropolymers could increase without a parallel increase in VDAC expression. Moreover, our Western blot analysis exclude that the majority FLAG-TSPO protein is expressed as a SDS and betamercaptoethanol resistant homopolymer. This explains why the silencing and up-regulation have similar effects on the cell growth. Indeed, the reduction of TSPO inside the pore makes the cells more resistant to endogenous apoptotic stimuli, as suggested by [35] while the increase of the monomeric form promote cholesterol transport [36] and, as a consequence, the biogenesis of the inner mitochondrial membrane that positively correlate with cell proliferation, motility and invasiveness.
Finally, it is well known that micromolar PK 11195 concentrations induce apoptosis in C6 glioma cells [18] . In the present study we tested the PK 11195 effects on cell viability of C6 glioma cells expressing different TSPO levels. We found that TSPO over-expression causes an increased susceptibility of C6 glioma cells to the antiproliferative activity of PK 11195, suggesting that this ligand may be useful also for the therapeutic treatment of gliomas with aggressive phenotype and high TSPO density.
